Article By:
Zacks Investment Research
Tuesday, March 27, 2018 8:42 AM EDT
After a solid run in the first two months of the first quarter, the drug/biotech sectors struggled in March, probably on broader market pressure and a few negative updates on the pipeline and regulatory front.